Targeted therapy in her2-positive metastatic breast cancer: a review of the literature.


Breast tumours positive for her2 (human epidermal growth factor receptor 2) represent approximately 20% of all breast cancer cases and are associated with an aggressive natural history. The advent of targeted anti-her2 therapies has dramatically improved disease control and survival in patients with metastatic her2-positive breast cancer. Targeted agents… (More)
DOI: 10.3747/co.22.2363


  • Presentations referencing similar topics